SCARPELLI, Marina
 Distribuzione geografica
Continente #
NA - Nord America 25.405
EU - Europa 10.665
AS - Asia 9.434
SA - Sud America 2.250
AF - Africa 529
Continente sconosciuto - Info sul continente non disponibili 463
OC - Oceania 7
Totale 48.753
Nazione #
US - Stati Uniti d'America 24.666
SG - Singapore 3.169
RU - Federazione Russa 2.451
VN - Vietnam 1.841
BR - Brasile 1.783
UA - Ucraina 1.580
IT - Italia 1.472
CN - Cina 1.295
IE - Irlanda 999
HK - Hong Kong 941
DE - Germania 908
SE - Svezia 870
TR - Turchia 813
FR - Francia 615
DK - Danimarca 576
FI - Finlandia 409
GB - Regno Unito 406
KR - Corea 326
CA - Canada 308
IN - India 249
CI - Costa d'Avorio 230
BD - Bangladesh 179
AR - Argentina 158
MX - Messico 132
NL - Olanda 88
EC - Ecuador 84
ID - Indonesia 81
ZA - Sudafrica 80
IQ - Iraq 78
MA - Marocco 68
CO - Colombia 67
JP - Giappone 64
CR - Costa Rica 63
PL - Polonia 58
PK - Pakistan 51
ES - Italia 49
VE - Venezuela 49
UZ - Uzbekistan 42
PH - Filippine 41
BE - Belgio 39
CW - ???statistics.table.value.countryCode.CW??? 32
GT - Guatemala 32
HN - Honduras 32
IL - Israele 32
TT - Trinidad e Tobago 31
SA - Arabia Saudita 30
CL - Cile 29
PR - Porto Rico 29
SV - El Salvador 28
TN - Tunisia 28
PY - Paraguay 27
NI - Nicaragua 26
EG - Egitto 24
DZ - Algeria 22
AE - Emirati Arabi Uniti 21
TH - Thailandia 21
AT - Austria 20
MY - Malesia 20
PE - Perù 20
EE - Estonia 19
JO - Giordania 18
RO - Romania 18
EU - Europa 17
JM - Giamaica 17
KE - Kenya 16
KZ - Kazakistan 16
BO - Bolivia 15
SC - Seychelles 15
UY - Uruguay 15
GP - Guadalupe 14
TW - Taiwan 14
ET - Etiopia 13
AZ - Azerbaigian 11
BH - Bahrain 11
CZ - Repubblica Ceca 11
NP - Nepal 11
OM - Oman 10
LB - Libano 9
PT - Portogallo 9
BG - Bulgaria 8
LT - Lituania 8
AL - Albania 7
AO - Angola 7
AU - Australia 7
GR - Grecia 7
KG - Kirghizistan 7
BB - Barbados 6
SY - Repubblica araba siriana 6
CH - Svizzera 5
DO - Repubblica Dominicana 5
HU - Ungheria 5
NG - Nigeria 5
PA - Panama 5
AM - Armenia 4
BY - Bielorussia 4
IR - Iran 4
PS - Palestinian Territory 4
SN - Senegal 4
GE - Georgia 3
MD - Moldavia 3
Totale 48.275
Città #
Ashburn 4.069
Singapore 2.052
Chandler 1.751
Jacksonville 1.639
Fairfield 1.437
Des Moines 1.205
Dallas 1.149
Dublin 997
Boardman 933
Hong Kong 905
San Jose 881
Council Bluffs 822
Wilmington 818
Woodbridge 644
New York 618
Ho Chi Minh City 605
Seattle 585
Houston 578
Cambridge 426
Princeton 426
The Dalles 415
Hanoi 410
Lawrence 402
San Mateo 390
Lauterbourg 360
Beijing 332
Milan 311
Ann Arbor 290
Los Angeles 267
Moscow 266
Abidjan 230
Centro 213
San Diego 182
São Paulo 179
Hefei 178
Santa Clara 141
Munich 116
Chicago 115
London 100
Haiphong 95
Da Nang 92
Buffalo 86
Pune 78
Orem 76
Helsinki 74
Phoenix 70
Shanghai 67
Mexico City 65
Washington 65
Montreal 63
Miano 62
Atlanta 60
Rome 58
Tokyo 53
Turku 53
Columbus 50
Rio de Janeiro 50
Turin 50
Vancouver 49
Brooklyn 48
San José 48
Warsaw 48
Redmond 47
Frankfurt am Main 46
Guangzhou 45
Norwalk 44
Salt Lake City 40
Tashkent 40
Denver 39
Izmir 39
Wuhan 39
Baghdad 38
Curitiba 38
Johannesburg 37
Toronto 35
Brussels 34
Guayaquil 34
San Francisco 34
Amsterdam 33
Chennai 33
Manchester 33
Willemstad 32
Porto Alegre 31
Ancona 30
Falls Church 29
Elk Grove Village 28
Guatemala City 28
Naples 28
Belo Horizonte 27
Biên Hòa 26
Hải Dương 26
Managua 26
Brasília 25
San Salvador 25
Stockholm 25
Can Tho 24
Dhaka 24
Jiaxing 23
Thái Nguyên 23
Boston 22
Totale 30.127
Nome #
Role of electron microscopy in the diagnosis of CADASIL syndrome: a study of 32 patients 777
Urethral caruncle: clinicopathologic features of 41 cases 283
Metabolic phenotype of bladder cancer 271
Morphometric index of adult renal cell carcinoma. Comparison with the Fuhrman grading system. 229
Mismatch repair deficiency may affect clinical outcome through immune response activation in metastatic gastric cancer patients receiving first-line chemotherapy 228
Prostatic Intraepithelial Neoplasia - Development of A Bayesian Belief Network For Diagnosis and Grading. 219
Immunotherapy in genitourinary cancers: Where are we going? 216
Are liver nested stromal epithelial tumors always low aggressive? 211
Impact of VEGF, VEGFR, PDGFR, HIF and ERCC1 gene polymorphisms on thymic malignancies outcome after thymectomy 207
Transcontinental communication and quantitative digital histopathology via the Internet; with special reference to prostate neoplasia 206
Ageing-related expression of Twinfilin-1 regulates cholangiocyte biological response to injury 206
A germline missense mutation in exon 3 of the MSH2 gene in a Lynch syndrome family: correlation with phenotype and localization assay 204
2004 WHO classification of the renal tumors of the adults. 201
Angiogenesis genotyping and clinical outcome during regorafenib treatment in metastatic colorectal cancer patients 201
BAP1, PBRM1 and SETD2 in clear-cell renal cell carcinoma: Molecular diagnostics and possible targets for personalized therapies 201
Lgr5 expression, cancer stem cells and pancreatic cancer: Results from biological and computational analyses 193
Androgen Receptor Signaling Pathway in Prostate Cancer: From Genetics to Clinical Applications 192
Standardized mitotic counts in breast cancer evaluation of the method 188
A rare case of chordoma and craniopharyngioma treated by an endoscopic endonasal, transtubercular transclival approach. 186
Biological issues with cabozantinib in bone metastatic renal cell carcinoma and castration-resistant prostate cancer 186
A new germline point mutation in Ret exon 8 (cys515ser) in a family with medullary thyroid carcinoma 185
"Pathological" reflection on European urology: extended, saturation, and systematic prostate biopsies. 182
Biomarkers of aggressiveness in genitourinary tumors with emphasis on kidney, bladder, and prostate cancer 180
Chromosomal Abnormalities in Macroscopically Normal Urothelium in Patiens with Bladder pT1 and pT2a Urothelial Carcinoma: a Fluorescence in situ hybridisation Study and Correlation with Histologic Features. 178
Re: Umberto Leone Roberti Maggiore, Simone Ferrero, Massimo Candiani, et al. Bladder Endometriosis: A Systematic Review of Pathogenesis, Diagnosis, Treatment, Impact on Fertility, and Risk of Malignant Transformation. Eur Urol 2017;71:790–807 178
KRAS: To be or not to be targeted? Biologic and computational analyses in pancreatic adenocarcinoma 178
Secondary neoplasms of the urinary system and male genital organs. 175
HER family receptor expression and prognosis in pancreatic cancer 173
HER2 expression and gene amplification in pT2a Gleason score 6 prostate cancer incidentally detected in cystoprostatectomies: comparison with clinically detected andreogen-dependent and androgen-independent cancer. 172
Adjuvant and neoadjuvant approaches for urothelial cancer: Updated indications and controversies 170
An observational retrospective analysis of the main metastatic site and corresponding locoregional treatment as a prognostic factor in metastatic gastric cancer 170
Prospective study of a molecular selection profile for RAS wild type colorectal cancer patients receiving irinotecan-cetuximab 169
Activity of chemokines in prostate and renal tumors and their potential role as future therapeutic targets 169
KRAS mutation status is associated with specific pattern of genes expression in pancreatic adenocarcinoma 168
Oligometastases in Genitourinary Tumors: Recent Insights and Future Molecular Diagnostic Approach 167
Nuclear changes in the normal-looking columnar epithelium adjacent to and distant from prostatic intraepithelial neoplasia and prostate cancer. Morphometric analysis in whole-mount sections. 166
Epithelial to Mesenchymal Transition in Renal Cell Carcinoma: Implications for Cancer Therapy 166
Genitourinary tumors: Update on molecular biomarkers for diagnosis, prognosis and prediction of response to therapy 166
Germline and somatic mutations in prostate cancer: Focus on defective DNA repair, PARP inhibitors and immunotherapy 166
Endoscopy-verified occult subependymal dissemination of glioblastoma and brain metastasis undetected by MRI: prognostic significance. 165
2004 World Health Organization Classification of the Noninvasive Urothelial Neoplasms: Inherent Problems and Clinical Reflections 165
Microbiome and cancers, with focus on genitourinary tumors 164
Contemporary best practice in the management of urothelial carcinomas of the renal pelvis and ureter 163
Morphologic, Molecular and Clinical Features of Aggressive Variant Prostate Cancer 162
Seminoma Retroperitoneal Relapse 23 Years After Surgery 162
Meningioma-like cerebral relapse of Hodgkin's disease. 160
Active surveillance for low-risk prostate cancer. 159
Immunohistochemical expression of somatostatin receptor subtypes in prostate tissue from cystoprostatectomies with incidental prostate cancer. 158
Metabolic Alterations in Renal and Prostate Cancer 158
Morphologic Variants of Epithelial and Neuroendocrine Tumors of the Prostate. The Pathologist's Point of View 158
The role of angiogenetic single-nucleotide polymorphisms in thymic malignancies and thymic benign lesions 156
Impact of phosphoinositide-3-kinase and vitamin D3 nuclear receptor single-nucleotide polymorphisms on the outcome of malignant melanoma patients 154
Bone targeting agents in patients with metastatic prostate cancer: State of the art 154
Added Clinical Value of Whole-mount Histopathology of Radical Prostatectomy Specimens: A Collaborative Review 154
Improving inter-observer agreement and certainty level in diagnosing and grading papillary urothelial neoplasms: usefulness of a Bayesian belief network. 153
2009 update on the classification of renal epithelial tumors in adults 153
Subarachnoid haemorrhage due to widely metastatising malignant ependymoma. 153
Resistance to systemic agents in renal cell carcinoma predict and overcome genomic strategies adopted by tumor 153
Adjuvant therapy in renal cell carcinoma: Is it the right strategy to inhibit VEGF? 153
Narrative review of prostate cancer grading systems: Will the Gleason scores be replaced by the grade groups? 152
Basal cell hyperplasia and basal cell carcinoma of the prostate: a comprehensive review and discussion of a case with c-erbB-2 expression. 151
Lynch syndrome-associated lung cancer: pitfalls of an immunotherapy-based treatment strategy in an unusual tumor type 150
Angioblastic parasellar extradural tumours. 149
An evaluation of current prostate cancer diagnostic approaches with emphasis on liquid biopsies and prostate cancer 149
MRI and pathological examination of post-mortem brains: the problem of white matter high signal areas. 148
A contemporary update on pathology reporting for urinary bladder cancer. 148
[Magnetic resonance in the pathologic evaluation of the isolated human brain]. 148
Targeted therapy for solid tumors and risk of hypertension: a meta-analysis of 68077 patients from 93 phase III studies 148
Is There a Role for Immunotherapy in Prostate Cancer? 148
Epileptogenic Low-Grade Tumours in Childhood: Outcome after Lesionectomy 147
A low grade PIN-like neoplasm of the transition zone immunohistochemically negative for basal cell markers: a possible example of low grade adenocarcinoma with stratified epithelium. 147
Adult primary paratesticular mesenchymal tumors with emphasis on a case presentation and discussion of spermatic cord leiomyosarcoma. 147
Genitourinary cancers: molecular determinants for personalized therapies 147
Rare synchronous association of vestibular schwannoma and indolent insular oligodendroglioma in a patient without neurofibromatosis: controversial issue of timing for surgical treatment of asymptomatic low-grade gliomas. 147
Pseudoxanthoma elasticum and skin: Clinical manifestations, histopathology, pathomechanism, perspectives of treatment 147
Seminal Vesicle Intraepithelial Neoplasia Versus Basal Cell Hyperplasia in a Seminal Vesicle. 145
Pd-l1 inhibitors for the treatment of prostate cancer 145
Prostatic Intraepithelial Neoplasia (pin) - Performance of Bayesian Belief Network For Diagnosis and Grading. 144
An overview of emerging immunotargets of genitourinary tumors 144
Contemporary grading of prostate cancer: 2017 update for pathologists and clinicians 144
Morphological diagnosis of urothelial neoplasms. 143
Quantitative-analysis of Prostatic Intraepithelial Neoplasia On Tissue-sections. 142
SURGICAL TREATMENT FOR GLIOBLASTOMA MULTIFORME: OUTCOME AND ANALYSIS OF PROGNOSTIC FACTORS ESPECIALLY ORIENTED TO THE EXTENT OF SURGICAL RESECTION 142
Current and emerging bladder cancer biomarkers with an emphasis on urine biomarkers 141
Computer assisted discrimination of glioblastomas 141
Occurrence of Cell-death (apoptosis) In Prostatic Intraepithelial Neoplasia 140
Mitochondrial encephalomyopathy lactic acidosis and strokelike episodes mimicking occipital idiopathic epilepsy. 140
Real-world data on cabozantinib in previously treated patients with metastatic renal cell carcinoma: Focus on sequences and prognostic factors 140
Variants and Variations in Epithelial Renal Cell Tumors in Adults: The Pathologist's Point of View 140
Epigenetic modifications and modulators in prostate cancer 140
Cardiac myxoma with glandular elements metastatic to the brain 12 years after the removal of the original tumor 139
Bladder cancer: molecular determinants of personalized therapy 139
TGFb1 immunohistochemistry in goiter; comparison of patients with recurrence or non recurrence 138
[Intracranial pressure in traumatic brain laceration and intracerebral hematomas (author's transl)]. 138
Combining radiotherapy with immunocheckpoint inhibitors or CAR-T in Renal Cell Carcinoma 138
The identification of immunological biomarkers in kidney cancers 138
Urothelial papillary lesions. Development of a Bayesian Belief Network for diagnosis and grading 137
"No pay, no play" or from "defensive or passive pathology" to "active, clinically oriented pathology" 137
Present and future of personalized medicine in adult genitourinary tumors 137
Pseudocarcinomatous hyperplasia associated with primary lymphoma in the urinary bladder: a case report 137
Totale 17.122
Categoria #
all - tutte 231.941
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 231.941


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.999 0 0 0 136 28 269 82 202 192 273 190 627
2022/20235.798 523 459 326 462 379 1.580 3 350 1.303 34 267 112
2023/20243.068 555 78 200 429 510 696 53 75 6 53 26 387
2024/20256.021 657 522 240 141 214 222 560 262 1.535 462 505 701
2025/202615.919 787 1.103 1.098 1.586 1.508 1.030 2.752 1.669 2.067 1.256 285 778
2026/20273.932 623 818 737 1.754 0 0 0 0 0 0 0 0
Totale 48.753